A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
Autor: | Luca Sforzini, Courtney Worrell, Melisa Kose, Ian M. Anderson, Bruno Aouizerate, Volker Arolt, Michael Bauer, Bernhard T. Baune, Pierre Blier, Anthony J. Cleare, Philip J. Cowen, Timothy G. Dinan, Andrea Fagiolini, I. Nicol Ferrier, Ulrich Hegerl, Andrew D. Krystal, Marion Leboyer, R. Hamish McAllister-Williams, Roger S. McIntyre, Andreas Meyer-Lindenberg, Andrew H. Miller, Charles B. Nemeroff, Claus Normann, David Nutt, Stefano Pallanti, Luca Pani, Brenda W. J. H. Penninx, Alan F. Schatzberg, Richard C. Shelton, Lakshmi N. Yatham, Allan H. Young, Roland Zahn, Georgios Aislaitner, Florence Butlen-Ducuing, Christine Fletcher, Marion Haberkamp, Thomas Laughren, Fanni-Laura Mäntylä, Koen Schruers, Andrew Thomson, Gara Arteaga-Henríquez, Francesco Benedetti, Lucinda Cash-Gibson, Woo Ri Chae, Heidi De Smedt, Stefan M. Gold, Witte J. G. Hoogendijk, Valeria Jordán Mondragón, Eduard Maron, Jadwiga Martynowicz, Elisa Melloni, Christian Otte, Gabriela Perez-Fuentes, Sara Poletti, Mark E. Schmidt, Edwin van de Ketterij, Katherine Woo, Yanina Flossbach, J. Antoni Ramos-Quiroga, Adam J. Savitz, Carmine M. Pariante |
---|---|
Přispěvatelé: | Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., Cowen, P. J., Dinan, T. G., Fagiolini, A., Ferrier, I. N., Hegerl, U., Krystal, A. D., Leboyer, M., McAllister-Williams, R. H., Mcintyre, R. S., Meyer-Lindenberg, A., Miller, A. H., Nemeroff, C. B., Normann, C., Nutt, D., Pallanti, S., Pani, L., Penninx, B. W. J. H., Schatzberg, A. F., Shelton, R. C., Yatham, L. N., Young, A. H., Zahn, R., Aislaitner, G., Butlen-Ducuing, F., Fletcher, C., Haberkamp, M., Laughren, T., Mantyla, F. -L., Schruers, K., Thomson, A., Arteaga-Henriquez, G., Benedetti, F., Cash-Gibson, L., Chae, W. R., De Smedt, H., Gold, S. M., Hoogendijk, W. J. G., Mondragon, V. J., Maron, E., Martynowicz, J., Melloni, E., Otte, C., Perez-Fuentes, G., Poletti, S., Schmidt, M. E., van de Ketterij, E., Woo, K., Flossbach, Y., Ramos-Quiroga, J. A., Savitz, A. J., Pariante, C. M., Institute of Psychiatry, Psychology & Neuroscience, King's College London, King‘s College London, Nutrition et Neurobiologie intégrée (NutriNeuro), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden = Dresden University of Technology (TU Dresden), The Florey Institute of Neuroscience and Mental Health, University of Melbourne, IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), European Project: (grant No 116060),IMPRiND |
Rok vydání: | 2022 |
Předmět: |
Depression
Diagnostic markers DISORDER STIMULATION STAR-ASTERISK-D SEROTONIN REUPTAKE INHIBITORS Major Depressive Disorder Clinical Trials and Supportive Activities Medical and Health Sciences Depressive Disorder Treatment-Resistant Cellular and Molecular Neuroscience REPORT QIDS-SR SDG 3 - Good Health and Well-being Clinical Research Humans RATING-SCALE Molecular Biology METAANALYSIS Psychiatry Depressive Disorder Major Depressive Disorder Treatment-Resistant Psychology and Cognitive Sciences Major REMISSION Biological Sciences Serious Mental Illness Brain Disorders Psychiatry and Mental health QUICK INVENTORY Mental Health Good Health and Well Being SYMPTOMATOLOGY [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] |
Zdroj: | Molecular psychiatry, vol 27, iss 3 Molecular Psychiatry Molecular psychiatry, Ahead of Molecular Psychiatry, 2021, 27 (3), pp.1286-1299. ⟨10.1038/s41380-021-01381-x⟩ Sforzini, L, Worrell, C, Kose, M, Anderson, I M, Aouizerate, B, Arolt, V, Bauer, M, Baune, B T, Blier, P, Cleare, A J, Cowen, P J, Dinan, T G, Fagiolini, A, Ferrier, I N, Hegerl, U, Krystal, A D, Leboyer, M, McAllister-Williams, R H, McIntyre, R S, Meyer-Lindenberg, A, Miller, A H, Nemeroff, C B, Normann, C, Nutt, D, Pallanti, S, Pani, L, Penninx, B W J H, Schatzberg, A F, Shelton, R C, Yatham, L N, Young, A H, Zahn, R, Aislaitner, G, Butlen-Ducuing, F, Fletcher, C, Haberkamp, M, Laughren, T, Mäntylä, F-L, Schruers, K, Thomson, A, Arteaga-Henríquez, G, Benedetti, F, Cash-Gibson, L, Chae, W R, de Smedt, H, Gold, S M, Hoogendijk, W J G, Mondragón, V J, Maron, E, Martynowicz, J, Melloni, E, Otte, C, Perez-Fuentes, G, Poletti, S, Schmidt, M E, van de Ketterij, E, Woo, K, Flossbach, Y, Ramos-Quiroga, J A, Savitz, A J & Pariante, C M 2022, ' A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials ', Molecular Psychiatry, vol. 27, pp. 1286-1299 . https://doi.org/10.1038/s41380-021-01381-x |
ISSN: | 1359-4184 1476-5578 |
DOI: | 10.1038/s41380-021-01381-x⟩ |
Popis: | Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the present document we used a Delphi-method-based consensus approach to define TRD and PRD and to serve as operational criteria for future clinical studies, especially if conducted for regulatory purposes. We reviewed the literature and brought together a group of international experts (including clinicians, academics, researchers, employees of pharmaceutical companies, regulatory bodies representatives, and one person with lived experience) to evaluate the state-of-the-art and main controversies regarding the current classification. We then provided recommendations on how to design clinical trials, and on how to guide research in unmet needs and knowledge gaps. This report will feed into one of the main objectives of the EUropean Patient-cEntric clinicAl tRial pLatforms, Innovative Medicines Initiative (EU-PEARL, IMI) MDD project, to design a protocol for platform trials of new medications for TRD/PRD. |
Databáze: | OpenAIRE |
Externí odkaz: |